Inclusion Criteria:
  -  Patients who fulfilled the following criteria were included in the study:
  -  Adult renal transplant patients (≥21years),
  -  Informed consent,
  -  Stable maintenance subcutaneous ESA therapy with constant dose interval during the last 2 months,
  -  Haemoglobin (Hb) ≥10mg/dL (Hct 32%),
  -  Transferrin saturation (TSAT) ≥20% (during the screening phase),
  -  and serum ferritin ≥100 ng/mL
Exclusion Criteria:
We excluded patients with the following criteria:
  -  Acute or chronic bleeding, or erythrocyte transfusion, within the preceding 8 weeks. change in Hb level ≥ 2 g/dL during screening phase,
  -  Hemolytic anemia,
  -  Recent infection or rejection,
  -  Diastolic blood pressure >100mmHg or discontinuation of ESA due to hypertension in the 6 months prior to study,
  -  Vitamin B12 or folic acid deficiency,
  -  Uncontrolled or secondary hyperparathyroidism,
  -  Acute or chronic systemic inflammatory disease and/or C-reactive protein (CRP) >30 mg/L,
  -  Hemodialysis due to failure of a kidney transplant,
  -  and malignancy
